Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

BACKGROUND: Therapeutic cancer vaccines have shown activity in metastatic castration-resistant prostate cancer (mCRPC), and methods are being assessed to enhance their efficacy. Ipilimumab is an antagonistic monoclonal antibody that binds cytotoxic T-lymphocyte-associated protein 4, an immunomodulat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Madan, Ravi A, Mohebtash, Mahsa, Arlen, Philip M, Vergati, Matteo, Rauckhorst, Myrna, Steinberg, Seth M, YTsang, Kwong, Poole, Diane J, Parnes, Howard L, Wright, John J, Dahut, William L, Schlom, Jeffrey, Gulley, James L
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2012
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6359905/
https://ncbi.nlm.nih.gov/pubmed/22326924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(12)70006-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi